Status
Conditions
Treatments
About
Atotal of 150 consecutive patients with chronic supraspinatous tendinopathy were invited to participate in the study .patients were recruited from the out patient clinic of rheumatology and rehabilitation department,Mansoura university hospital
a. perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection .
Full description
Baseline Evaluation
All patients were subjected to the following:
Thorough History Taking
Personal history: collected data include: age, sex, marital status, handedness, special habits and the current occupation.
Complaint in the patient's own words.
Present History he current symptoms, mode of onset, duration, , factors that may aggravate or relieve pain Characters of pain (dull aching,sharp pain ,burning sensation ,parasthesia). Distribution of pain . Review of systems: symptoms related to rheumatic conditions in particular conditions with predilection for shoulder joint affection.
Symptoms suggestive of medical disorders e.g. diabetes mellitus or thyroid dysfunction.
Past History Previous significant trauma(direct or occupational) orsugery to shoulder. Previous steroid injection to the shoulder. Previous injection of any type of regenerative medicine (as prp)
Thorough General Examination
General condition.
Vital signs (pulse, blood pressure, respiratory rate, body temperature)
Examination of systems (chest,cardiovascular,abdominal,neurological) to identify medical condition that may cause shoulder pain.
3-Muscloskeletal examination
Examination of all joints for :
I.deformity,visible swelling or muscle atrophy II.Palpation for tenderness,warmth,palpable swelling either bony enlargement or synovial effusion.
III.Abnormalities in range of motion. IV.Diffuse muscloskeletal pain. V.Abnormalities of gait.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with supraspinatous tendinopathy
Exclusion criteria
-Shoulder joint instability omplete rotator cuff tear Adhesive capsulitis Septic arthritis Malignancy Coagulopathy Connective tissue diseases Spondyloarthropathies Previous corticosteroid injection in the last six months. Previous other forms of regenerative injection therapy (e.g prp injection therapy) in the last six mo
Primary purpose
Allocation
Interventional model
Masking
60 participants in 2 patient groups
Loading...
Central trial contact
Reham M. Shaat
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal